In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Pfizer hands over EGFR inhibitor to partner OSI

Executive Summary

Pfizer is relinquishing to OSI Pharmaceuticals, royalty-free, all development and marketing rights to CP-358,774 (OSI-774), an oral inhibitor of the epidermal growth factor receptor oncogene that the companies have been developing since 1986. Because Pfizer is acquiring Warner-Lambert, which is also developing an EGFR inhibitor, the FTC is requiring it to divest the product.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Contract
    • Includes Royalty or Profit Split Information
    • Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register